Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Thomas Zindrick, President and Chief Executive Officer, rings the Opening Bell.
